Amino Acid Sequence Disclosed In Whole Or In Part; Or Conjugate, Complex, Or Fusion Protein Or Fusion Polypeptide Including The Same Patents (Class 424/185.1)
-
Patent number: 10765719Abstract: Prophylactic and/or therapeutic antipathogen agents are provided that disrupt or prevent the formation of at least one homotypic and/or heterotypic protein-protein interaction that has at least one CEA-family protein and that is involved in the establishment and colonization of a pathogen in a suitable host.Type: GrantFiled: February 13, 2018Date of Patent: September 8, 2020Inventor: Gal Markel
-
Patent number: 10766926Abstract: Provided are a polypeptide having the activity of inhibiting autophagy in a cell, a composition for inhibiting autophagy in a cell, and particularly in a tumor cell, containing the polypeptide as an active ingredient, and a pharmaceutical composition containing the polypeptide, and more specifically, a composition for inhibiting autophagy in a cell containing a polypeptide inhibiting the control mechanism of autophagy as an active ingredient, and a pharmaceutical composition for preventing or treating a neoplastic disease or for inhibiting resistance to anticancer agents, containing the polypeptide.Type: GrantFiled: May 28, 2018Date of Patent: September 8, 2020Assignee: L-BASE CO., LTDInventors: Do Yong Jeon, Chang Hoon Moon, Ji Eun Jung
-
Patent number: 10759863Abstract: The present invention relate to the discovery that BTLA, IL-7 and ROR?t modulate the activity and expression of ??T cells. Specifically, the present invention provides methods of modulating ??T cell homeostasis and function by regulating expression of BTLA. The present invention further provides agents which modulate the activity and expression of BTLA, RORyt and IL-7 and methods for screening of such agents. The present invention also provides methods for treating autoimmune or inflammatory diseases using modulators of BTLA, RORyt and IL-7.Type: GrantFiled: September 4, 2014Date of Patent: September 1, 2020Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTEInventors: Carl F. Ware, John R. Sedy
-
Patent number: 10759838Abstract: Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.Type: GrantFiled: March 9, 2016Date of Patent: September 1, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Michael J. Lenardo, Jian Li, Lixin Zheng, Jae W. Lee, Wei Lu
-
Patent number: 10758612Abstract: The present disclosure relates to antibodies specific tumor associated complex N-glycans with terminal GlcNAc? residues and methods for detecting a tumor in a subject. The present disclosure also relates to therapeutic antibodies specific for tumor associated complex N-glycans with terminal GlcNAc? residues.Type: GrantFiled: July 15, 2016Date of Patent: September 1, 2020Inventor: Mai Xu
-
Patent number: 10753946Abstract: The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70% with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4. The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.Type: GrantFiled: July 20, 2015Date of Patent: August 25, 2020Assignee: PHADIA ABInventors: Lars Mattsson, Ulrica Olsson, Thomas Lundgren, Jonas Lidholm, HÃ¥kan Larsson
-
Patent number: 10730910Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: January 24, 2020Date of Patent: August 4, 2020Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Juliane Walz, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
-
Patent number: 10729791Abstract: The application relates to methods for determining a parameter such as toxicity and pharmacokinetic behavior for a pharmaceutical compound against a disease or disorder. The test animals being used are non-human animals not suffering from or is not showing symptoms or signs of the disorder and which do not provoke an immune response against said pharmaceutical compound. These animals are obtainable by administration of a peptide comprising an oxidoreductase motif further comprising an NKT peptide epitope or an MHC class II T cell epitope of said pharmaceutical compound, wherein said motif and said epitope are separated by a linker of between 0 and 4 amino acids.Type: GrantFiled: May 11, 2016Date of Patent: August 4, 2020Assignee: IMCYSE SAInventors: Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier
-
Patent number: 10722555Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).Type: GrantFiled: December 18, 2014Date of Patent: July 28, 2020Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLCInventor: Xiaodong Feng
-
Patent number: 10721629Abstract: Dynamic sharing of pooled radio access network (RAN) resources can be divided amongst different tenant carriers according to a service level agreement and/or a host carrier policy. The carriers can share the RAN with the host carrier while utilizing their own core network and service delivery platform. The hosting carrier can utilize policies to provide guidelines on how to share among the tenant carriers. Additionally, the hosting carrier can also provide services for internet-of-things devices based on security requirements with different firewall, and/or authentication requirements.Type: GrantFiled: August 14, 2019Date of Patent: July 21, 2020Assignees: AT&T Intellectual Property I, L.P., AT&T Mobility II LLCInventors: Zhi Cui, Erie Lai Har Lau, Sangar Dowlatkhah
-
Patent number: 10717766Abstract: A fragment of a virulent peptide named phenol-soluble modulin (PSM) having anti-bacterial activity and methods for eliminating bacteria are provided.Type: GrantFiled: August 22, 2017Date of Patent: July 21, 2020Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITEDInventors: Meytal Landau, Asher Moshe, Nir Salinas
-
Patent number: 10718779Abstract: Provided are methods for determining the amount of thyroglobulin in a sample using various purification steps followed by mass spectrometry. The methods generally involve purifying thyroglobulin in a test sample, digesting thyroglobulin to form peptide T129, purifying peptide T129, ionizing peptide T129, detecting the amount of peptide T129 ion generated, and relating the amount of peptide T129 ion to the amount of thyroglobulin originally present in the sample.Type: GrantFiled: January 28, 2019Date of Patent: July 21, 2020Assignee: Quest Diagnostics Investments IncorporatedInventors: Yanni Zhang, Nigel J. Clarke, Richard E. Reitz
-
Patent number: 10702541Abstract: A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in R1 is a quaternary ammonium group, Y1 is a spacer chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, R2 and R3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof.Type: GrantFiled: September 12, 2017Date of Patent: July 7, 2020Assignee: PDS Biotechnology CorporationInventors: Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya N. Toney Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
-
Patent number: 10695411Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: November 4, 2019Date of Patent: June 30, 2020Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10675339Abstract: The present invention relates to methods for the recombinant expression of Chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes Chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of Chlamydia infection and/or the effects thereof.Type: GrantFiled: November 16, 2015Date of Patent: June 9, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Lan Zhang, Zhiyun Wen, Craig T. Przysiecki, Puneet Khandelwal
-
Patent number: 10648966Abstract: A conductive channel-containing membrane includes a membrane layer, and a SPP1 connector polypeptide variant that is incorporated into the membrane layer to form an aperture through which conductance can occur when an electrical potential is applied across the membrane. A method of sensing a molecule, such as a polypeptide or nucleic acid molecule, makes use of the conductive channel-containing membrane. A method of DNA sequence makes use of the conductive channel-containing membrane.Type: GrantFiled: January 15, 2016Date of Patent: May 12, 2020Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventors: Peixuan Guo, Shaoying Wang
-
Patent number: 10626174Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.Type: GrantFiled: August 17, 2016Date of Patent: April 21, 2020Assignee: Genentech, Inc.Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
-
Patent number: 10624934Abstract: Provided herein are compositions comprising a biocompatible microsphere, a biofilm-generating probiotic bacterium, a prebiotic, and/or a prebiofilmic. Methods for preparing and formulating the compositions and methods for treating or preventing a disease using the compositions are also provided.Type: GrantFiled: July 13, 2017Date of Patent: April 21, 2020Assignees: Research Institute at Nationwide Children's Hospital, Ohio State Innovation FoundationInventors: Steven D. Goodman, Lauren O. Bakaletz, Michael Bailey, Gail Besner
-
Patent number: 10617748Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumor-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the treatment of a tumor or in the treatment or prevention of a tumor relapse, and in the manufacture of medicaments therefore.Type: GrantFiled: January 5, 2015Date of Patent: April 14, 2020Assignees: LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVENInventor: Jean-Marie Saint-Remy
-
Patent number: 10610585Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).Type: GrantFiled: September 25, 2018Date of Patent: April 7, 2020Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Baylor Research Institute, Universite Paris Est Creteil Val De Marne, Assistance Publique Hopitaux de ParisInventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
-
Patent number: 10611836Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.Type: GrantFiled: August 17, 2016Date of Patent: April 7, 2020Assignee: Genentech, Inc.Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
-
Patent number: 10610574Abstract: Methods of treating an age-related disorder in a subject are provided. Aspects of the methods include administering to the subject a nucleic acid vector including a coding sequence for telomerase reverse transcriptase (TERT) and/or telomerase RNA (TR). Gene therapy methods are also provided. Aspects of the invention further include compositions, e.g., nucleic acid vectors and kits, etc., that find use in methods of the invention.Type: GrantFiled: July 26, 2016Date of Patent: April 7, 2020Assignee: Sierra Sciences, LLCInventors: William H. Andrews, Lancer K. Brown, Hamid Mohammadpour, Laura A. Briggs
-
Patent number: 10604570Abstract: The present invention relates to a chimeric antigen-receptor (CAR) signalling system comprising; (i) a targeting component comprising an antigen-binding domain, a transmembrane domain and a first heterodimerization domain; and (ii) an intracellular signalling component comprising a signalling domain and a second heterodimerization domain; wherein spontaneous heterodimerization between the first and second heterodimerization domains causes the targeting component and signalling component to form a functional CAR complex.Type: GrantFiled: February 4, 2016Date of Patent: March 31, 2020Assignee: UCL BUSINESS LTDInventors: Martin Pulé, Shaun Cordoba
-
Patent number: 10590169Abstract: Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.Type: GrantFiled: December 9, 2016Date of Patent: March 17, 2020Assignee: Virogin Biotech Canada LtdInventors: William Jia, Xuexian Bu, I-Fang Lee
-
Patent number: 10583199Abstract: Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.Type: GrantFiled: November 8, 2017Date of Patent: March 10, 2020Assignee: Northwestern UniversityInventors: Jack Henkin, Ignacio Melgar-Asensio
-
Patent number: 10570175Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: May 24, 2019Date of Patent: February 25, 2020Assignee: Immatics Biotechnologies GmbHInventors: Juliane Walz, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
-
Patent number: 10568926Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present disclosure relates to the use of des-aspartate-angiotensin I and/or its derivatives that are its metabolites for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions. Specifically, the disclosure relates to the treatment of a malignant growth, an invasive growth, a tumor, a tumor metastasis, a cancer or combinations thereof and to modulate the level or effect of HSP90 or other inflammation-linked molecules in relevant tissue or blood.Type: GrantFiled: June 5, 2017Date of Patent: February 25, 2020Assignee: SimPharma Pte LtdInventor: Meng Kwoon Sim
-
Patent number: 10563224Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.Type: GrantFiled: February 15, 2017Date of Patent: February 18, 2020Assignee: Etubics CorporationInventors: Frank R. Jones, Elizabeth Gabitzsch
-
Patent number: 10556002Abstract: Bivalent immunogenic compositions against anthrax and plague are disclosed herein. One bivalent immunogenic composition comprises a triple fusion protein containing three antigens, F1 and V from Yersinia pestis and PA antigen from Bacillus anthracia fused in-frame and retaining structural and functional integrity of all three antigens. Another bivalent immunogenic composition comprises bacteriophage nanoparticles arrayed with these three antigens on the capsid surface of the bacteriophage nanoparticles. These bivalent immunogenic compositions are able to elicit robust immune response in a subject administered said the bivalent immunogenic compositions and provide protection to the subject against sequential or simultaneous challenge with both anthrax and plague pathogens.Type: GrantFiled: February 9, 2018Date of Patent: February 11, 2020Assignee: The Catholic University of AmericaInventor: Venigalla B. Rao
-
Patent number: 10555990Abstract: The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.Type: GrantFiled: August 21, 2018Date of Patent: February 11, 2020Assignees: NOVARTIS AG, THE SCRIPPS RESEARCH INSTITUTEInventors: Lori Jennings, Kristen Johnson, Peter Schultz
-
Patent number: 10548976Abstract: Provided herein are methods of treating beta-thalassemia in a subject comprising administering to the subject an activin type II receptor (ActRII) signaling inhibitor (e.g., an activin ligand trap) and utilizing one or more in vitro cell culture methods provided herein in (i) selection of the subject to be treated according to the methods provided herein; and/or (ii) monitoring of the subject being treated according to the methods provided herein.Type: GrantFiled: May 19, 2016Date of Patent: February 4, 2020Assignee: Celgene CorporationInventors: Maria Cappellini, Victoria Sung
-
Patent number: 10537610Abstract: Methods for treating breast cancer, the methods can include administering to a subject an effective amount of a cell adhesion molecule Receptor (F11R peptide).Type: GrantFiled: October 24, 2018Date of Patent: January 21, 2020Inventors: Anna Babinska, Radoslaw Bednarek, Elizabeth Kornecki, Moro O. Salifu, Yigal H. Ehrlich, Maria Swiatkowska, Cristina C. Clement
-
Patent number: 10537626Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.Type: GrantFiled: October 7, 2015Date of Patent: January 21, 2020Assignee: Cytlimic Inc.Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
-
Patent number: 10526386Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: May 4, 2016Date of Patent: January 7, 2020Assignee: Immatics Biotechnologies GMBHInventors: Oliver Schoor, Andrea Mahr, Toni Weinschenk, Anita Wiebe, Jens Fritsche, Harpreet Singh
-
Patent number: 10512679Abstract: The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: March 14, 2017Date of Patent: December 24, 2019Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Oliver Schoor, Andrea Mahr
-
Patent number: 10500261Abstract: The invention relates to immunogenic synthetic constructs capable of inducing an immune response against Campylobacter jejuni (C. jejuni) in a subject comprising one or more monosaccharides comprising one or more MeOPN moieties. Specifically, the invention relates to immunogenic synthetic constructs capable of inducing an immune response against C. jejuni in a subject comprising one or more MeOPN-6-Gal monosaccharides, one or more MeOPN-4-Gal monosaccharides, and/or one or more MeOPN-2-Gal monosaccharides. The invention also relates to compositions comprising the immunogenic synthetic constructs, and methods of inducing an immune response against C. jejuni in a subject comprising administering the immunogenic synthetic constructs, and/or compositions comprising the immunogenic synthetic constructs, to the subject. Methods of treating, preventing, or ameliorating a C.Type: GrantFiled: November 3, 2016Date of Patent: December 10, 2019Assignee: The United States of America as represented by the Secretary of the NavyInventors: Patricia Guerry, Mario Artur Monteiro, Yuening Jiao, Brittany Michele Pequegnat
-
Patent number: 10494408Abstract: Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.Type: GrantFiled: December 20, 2017Date of Patent: December 3, 2019Assignee: Monsanto Technology LLCInventors: James A. Baum, Thomas A. Cerruti, Crystal L. Dart, Leigh H. English, Stanislaw Flasinski, Xiaoran Fu, Victor M. Guzov, Arlene R. Howe, Jay P. Morgenstern, James K. Roberts, Sara A. Salvador, Jinling Wang
-
Patent number: 10487143Abstract: The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to antigenic polypeptides and their use in cancer vaccines that may be used, in part, to treat cancer types dependent upon HER2-mediated signaling.Type: GrantFiled: October 5, 2017Date of Patent: November 26, 2019Assignee: Duke UniversityInventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
-
Patent number: 10478471Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.Type: GrantFiled: July 3, 2019Date of Patent: November 19, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
-
Patent number: 10464977Abstract: Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.Type: GrantFiled: April 11, 2017Date of Patent: November 5, 2019Assignees: University of Maryland, Baltimore, University of Maryland, College ParkInventors: Mary Ann Jabra-Rizk, Amy J. Karlsson, Svetlana Pavlova Ikonomova
-
Patent number: 10463747Abstract: The invention describes the development of more potent peptide vaccines to prevent or treat infections or cancer and their administration to a subject in order to elicit a T cell response in the subject. Small synthetic peptides from the known sequences of viral, bacterial, parasitic or tumor antigens are modified so they can spontaneously form complexes with a synthetic nucleic acid, such as Poly IC, that functions as an immunological adjuvant. The peptide-nucleic acid complexes are dramatically more immunogenic as compared to the separate components. The procedure for developing the vaccine involves the conjugation of a synthetic peptide containing a C residue to poly-K using a bi-functional cross-linking reagent (SMCC). The peptide/poly-K complex was then formulated with CMC and poly-IC to produce a self-adjuvant vaccine that was 36-fold more effective as compared to the same peptide administered mixed with the same adjuvant (but not complexed to it).Type: GrantFiled: August 21, 2017Date of Patent: November 5, 2019Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventor: Esteban Celis
-
Patent number: 10449250Abstract: Provided is a humanized antibody and chimeric antibody that specifically binds human sclerostin. The antibodies can be used for treating human bone metabolism related diseases such as osteoporosis (OP).Type: GrantFiled: February 16, 2016Date of Patent: October 22, 2019Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Jiajian Liu, Yayuan Fu, Haoying Zhang, Yifang Wang, Zhen Zhang, Ling Zhang, Dongbing Cui, Lianshan Zhang, Weikang Tao
-
Patent number: 10441649Abstract: A variety of targeting moiety peptide epitope complexes (TPECs) are described in different embodiments. In each of the embodiments, however, a targeting moiety may be used to deliver the TPEC to an area of unwanted cells, allowing for a therapeutic effect to be delivered locally. The TPEC also contains a plurality of T-cell epitopes. The TPEC further comprises cleavage sites that release the T-cell epitopes from the targeting agent, and in some embodiments from each other, when they are in the microenvironment of the unwanted cells. Although the arrangement and number of T-cell epitopes varies in different embodiments described herein, once cleaved from the targeting agent (and any neighboring T-cell epitopes), the T-cell epitopes function by stimulating an immune response against the unwanted cells.Type: GrantFiled: February 1, 2016Date of Patent: October 15, 2019Assignee: The University of BirminghamInventors: Mark Cobbold, David Millar
-
Patent number: 10435449Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: April 10, 2019Date of Patent: October 8, 2019Assignee: INMATICS BIOTECHNOLOGIES GMBHInventors: Colette Song, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
-
Patent number: 10420816Abstract: A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.Type: GrantFiled: May 22, 2019Date of Patent: September 24, 2019Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
-
Patent number: 10420801Abstract: A method for suppressing an immune response is provided. The method involves administration of isolated lymphoid tissue-derived suppressive stromal cells (LSSC) to a subject in need of such treatment in an amount effective to suppress the immune response in the subject. The invention also involves a method to isolate LSSC by digesting lymphoid tissue fragments using a combination of an enzyme mix and agitation and then collecting the LSSC. Pharmaceutical preparations comprising LSSC are also provided.Type: GrantFiled: March 13, 2013Date of Patent: September 24, 2019Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.Inventors: Anne Fletcher, Shannon J. Turley, Biju Parekkadan
-
Patent number: 10407697Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.Type: GrantFiled: February 16, 2017Date of Patent: September 10, 2019Assignees: The Regents of the University of California, University of ViennaInventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
-
Patent number: 10398905Abstract: The present invention relates to methods for delivering at least one agent unto or into a biological sample or a biological subject. The methods comprise a step of contacting the biological sample or subject with a payload-carrying nanostructure. The nanostructure can be a porous low density nanostructure.Type: GrantFiled: February 19, 2013Date of Patent: September 3, 2019Assignee: NVIGEN, INC.Inventor: Aihua Fu
-
Patent number: 10383928Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.Type: GrantFiled: April 27, 2017Date of Patent: August 20, 2019Assignee: ULTIMOVACS ASInventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
-
Patent number: RE48023Abstract: A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.Type: GrantFiled: May 18, 2016Date of Patent: June 2, 2020Assignee: EYEGENE INC.Inventors: Doo-Sik Kim, Yang-Je Cho, Won-Il Yoo, Oh-Woong Kwon, Jin-Wook Jang, Hyeong-Joon Lim, Soo-Mee Kwon